Novo Holdings
Overview
Novo Holdings is a holding and investment company that manages the assets and wealth of the Novo Nordisk Foundation. It is the controlling shareholder of Novo Nordisk A/S and Novonesis A/S (formerly Novozymes A/S). Novo Holdings invests in life science companies at all stages of development and manages a broad portfolio of equities, bonds, real estate, infrastructure, and private equity assets.
Investments
| Company | Date | Stage | Lead |
|---|---|---|---|
| ImmuneBiotech | May 2026 | Growth Equity | Co-investor |
| Windward Bio | May 2026 | Growth Equity | Co-investor |
| Coultreon Biopharma | Apr 2026 | Series A | Lead |
| Ray Therapeutics | Apr 2026 | Series B | Co-investor |
| Route 92 Medical | Apr 2026 | Series F Extension | Lead |
Key People
Anders Spohr
Managing Partner, Head Of Planetary Health Investments
Robert Ghenchev
Managing Partner, Growth Investments
Scott Beardsley
Managing Partner, Venture Investments, Novo Holding US
Abhijeet Lele
Senior Partner And Head Of US Principal Investments
Daniel Mahony
Senior Partner, Novo Growth Investments
Jacob Lise Lyngsgaard
Senior Partner, Head Of Real Assets
Johan Hueffer
Senior Partner
Jonathan Levy
Senior Partner
Ken Harrison
Senior Partner
Naveed Siddiqi
Senior Partner, Partner
Søren Thinggaard Hansen
Senior Partner Head Of Private Equity
Aaron Nelson
Partner
Aleks Engel
Partner, Novo Holdings (Planetary Health Investments)
Andreas Nahne Nickelsen
Partner, Real Estate
Camilla Petrycer Hansen
Partner, Novo Holdings And REPAIR Impact Fund
Charles Patten
Partner, Private Equity
Sector & Stage Mix
Industry, funding stage, and valuation band breakdowns.
